India’s pharmaceutical exports are expected to soar to a record $31 billion in the fiscal year 2025, with growth of over 11% anticipated due to a number of important variables, most notably the scarcity of medications in the vital U.S. market. During the PharmaLytica expo and conference in Hyderabad, Ravi Uday Bhaskar, Director General of the Pharmaceuticals Export Promotion Council of India, a body under the Commerce Ministry, revealed this forecast.
Pharmaceutical exports from India, which make up a sizeable portion of the nation’s international trade, climbed by 9.6% to $27.8 billion for the fiscal year that ends in March 2024. This expansion was attained in spite of several worldwide obstacles. More than half of these exports, Bhaskar noted, went to heavily regulated markets in North America and Europe. In particular, pharmaceutical exports to the United States increased by 15% to surpass $8 billion, while exports to the United Kingdom increased by 21% to $783 million. These numbers demonstrate the pharmaceutical industry’s strong expansion in India, despite difficult circumstances.
India’s capacity to develop high-quality pharmaceuticals at reasonable prices is credited with the country’s good success in pharmaceutical exports. India is now a major player in the global pharmaceutical business thanks to this expertise. However, the sector has encountered a number of difficulties, including as logistical difficulties, economic downturns, and geopolitical unrest. Over the previous fiscal year, the Indian pharmaceutical industry also had to contend with quality-related problems.
Bhaskar expounded on the present and upcoming patterns of India’s pharmaceutical exports during an interview with The Hindu. He made the point that the closure of some production facilities in the United States is likely to worsen the scarcity of generic prescription medications. Given the circumstances, Indian pharmaceutical businesses have a great chance to close the gap and satisfy the rising demand in the US market for generic medications.
Furthermore, it is projected that demand for pharmaceutical shipments to Africa will rise. Many non-governmental organizations (NGOs) temporarily redirected resources from the provision of free drugs for other health issues to combat the virus during the COVID-19 pandemic. The need for pharmaceuticals in African markets is anticipated to increase when these organizations return to their pre-pandemic priorities. The pharmaceutical exports to Africa experienced a 5% fall in FY23 but an 8% growth in the most recent fiscal year, largely due to this shift.
Positive growth was also evident in the export patterns of pharmaceuticals to other regions. Exports to every market in FY24 increased year over year, with the exception of the nations that make up the Commonwealth of Independent States (CIS). This wide-ranging expansion suggests that there is a robust demand for Indian drugs around the world. Pharmaceutical exports increased by more than 7% in April 2024, indicating that the increasing trend is probably going to continue as a predictor of future prospects.
India’s growth in pharmaceutical exports is attributed to a number of underlying factors. The nation’s vast manufacturing infrastructure, which enables the large-scale production of both branded and generic medications, is one important contributing element. Indian pharmaceutical companies have made significant investments in cutting-edge, internationally compliant manufacturing facilities. Due to their adherence to strict regulatory regulations, Furthermore, the pharmaceutical industry in India has robust government assistance. The Indian government has launched a number of programs and policies to encourage the expansion of the pharmaceutical industry. These consist of tax breaks, R&D incentives, and expedited regulatory procedures to speed up the approval of novel medications. Because of the government’s aggressive stance, the pharmaceutical business is thriving in this favorable atmosphere.
But in order to maintain expansion, the industry must also solve certain issues. Concerns about quality have been raised a lot, and certain Indian pharmaceutical businesses are now being investigated by foreign regulators. Maintaining the industry’s reputation and access to markets requires constant adherence to quality standards and international laws.
Another obstacle facing the pharmaceutical sector is logistical. Effective supply chain management is necessary to guarantee pharmaceutical products are delivered to international markets on schedule. To optimize supply chain operations and reduce interruptions, the sector needs to make significant investments in a strong logistical infrastructure and cutting-edge technologies.
SOURCE:
MEDICAL DIALOGUES
